Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants

Metabolic-dysfunction-associated steatotic liver disease (MASLD), which affects 30 million people in the US and is anticipated to reach over 100 million by 2030, places a significant financial strain on the healthcare system. There is presently no FDA-approved treatment for MASLD despite its public...

Descripción completa

Detalles Bibliográficos
Autores principales: Faccioli, Lanuza A. P., Cetin, Zeliha, Kocas-Kilicarslan, Zehra N., Ortiz, Kimberly, Sun, Yiyue, Hu, Zhiping, Kurihara, Takeshi, Tafaleng, Edgar N., Florentino, Rodrigo M., Wang, Zi, Xia, Mengying, Miedel, Mark T., Taylor, D. Lansing, Behari, Jaideep, Ostrowska, Alina, Constantine, Robert, Li, Albert, Soto-Gutierrez, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487897/
https://www.ncbi.nlm.nih.gov/pubmed/37686209
http://dx.doi.org/10.3390/ijms241713406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487897/
https://www.ncbi.nlm.nih.gov/pubmed/37686209
http://dx.doi.org/10.3390/ijms241713406

Ejemplares similares